Amygdala Neurosciences Selects ANS-858 for Clinical Development as a Novel ALDH2 Inhibitor for Substance Use Disorder

Posted on by sHq_LoGiNz

The discovery and preclinical efficacy of ANS-858, a proprietary, selective, reversible, orally bioavailable ALDH2 inhibitor will be presented at 48th Annual Scientific Meeting of the Research Society on Alcohol. SAN FRANCISCO, April 2, 2025 /PRNewswire/ — Amygdala Neurosciences, Inc., a…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.